These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 20620443)

  • 1. Response to Gaber.
    Sollinger H; Neidlinger NA
    Transplant Proc; 2010 Jun; 42(5):1401. PubMed ID: 20620443
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab in kidney-transplant recipients.
    Markmann JF; Fishman JA
    N Engl J Med; 2011 May; 364(20):1968-9. PubMed ID: 21591949
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab in kidney-transplant recipients.
    Luan FL
    N Engl J Med; 2011 Aug; 365(7):671; author reply 671-2. PubMed ID: 21848469
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy.
    Heidt S; Shankar S; Muthusamy AS; San Segundo D; Wood KJ
    Transplantation; 2011 Apr; 91(8):e59-61. PubMed ID: 21475065
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
    Plata-Munoz JJ; Vaidya A; Fuggle SV; Friend PJ
    Transpl Int; 2009 Oct; 22(10):1024-7. PubMed ID: 19624499
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term results of rabbit antithymocyte globulin and basiliximab induction.
    Brennan DC; Schnitzler MA
    N Engl J Med; 2008 Oct; 359(16):1736-8. PubMed ID: 18923181
    [No Abstract]   [Full Text] [Related]  

  • 7. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithymocyte globulin versus basiliximab in renal transplantation.
    Killen JP; Chadban S
    N Engl J Med; 2007 Feb; 356(6):634; author reply 634-5. PubMed ID: 17287486
    [No Abstract]   [Full Text] [Related]  

  • 9. Rabbit antithymocyte globulin or basiliximab for induction therapy?
    Josephson MA
    N Engl J Med; 2006 Nov; 355(19):2033-5. PubMed ID: 17093255
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies.
    Delmonico FL; Knowles RW; Colvin RB; Cavender DE; Kawai T; Bedle M; Stroka D; Preffer FI; Haug C; Cosimi AB
    Transplant Proc; 1993 Feb; 25(1 Pt 1):784-5. PubMed ID: 8438479
    [No Abstract]   [Full Text] [Related]  

  • 11. Could prophylactic monoclonal antibody improve kidney graft survival?
    Pourmand G; Saraji A; Salem S; Mehrsai A; Nikoobakht MR; Taherimahmoudi M; Rezaeidanesh M; Asadpour A
    Transplant Proc; 2009 Sep; 41(7):2794-6. PubMed ID: 19765437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal antibodies in renal transplantation].
    Bonvoisin C; Weekers L; Grosch S; Krzesinski JM
    Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
    Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
    Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation.
    Tchervenkov J; Flemming C; Guttmann RD; des Gachons G
    Transplant Proc; 1997 Nov; 29(7A):13S-15S. PubMed ID: 9366919
    [No Abstract]   [Full Text] [Related]  

  • 16. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.
    McCurry KR; Iacono A; Zeevi A; Yousem S; Girnita A; Husain S; Zaldonis D; Johnson B; Hattler BG; Starzl TE
    J Thorac Cardiovasc Surg; 2005 Aug; 130(2):528-37. PubMed ID: 16077423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
    Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
    Agarwal A; Shen LY; Kirk AD
    Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of induction therapy on peripheral blood lymphocytes after lung transplantation: A multicenter international study.
    Coiffard B; Piloni D; Boucekine M; Morosini M; Meloni F; Kessler R; Reynaud-Gaubert M
    Transpl Immunol; 2018 Jun; 48():47-54. PubMed ID: 29475091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.